(*) EU Approval Date: 2019. 08.
(*) USA Approval Date: 2019. 10.21.
>ion Risk Reduction: Dapagliflozin
Company
Mechanism: SGLT2 Inhibition
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 7
Patent>UpDate: 2019. 10.22.
TradeMark
TradeMark Web-Site